Jade Biosciences (JBIO) Insiders Sell $225K Worth of Shares on Nasdaq

Form 144 Notice of Proposed Sale filed by Atlas Ventures for Jade Biosciences (NASDAQ: JBIO) indicates planned insider stock sales.

Rhea-AI Filing Summary

Form 144 Notice of Proposed Sale filed by Atlas Ventures for Jade Biosciences (NASDAQ: JBIO) indicates planned insider stock sales. The filing details a proposed sale of 131 shares at an aggregate market value of $1,292.97 through Merrill Lynch, with execution planned for June 24, 2025.

Key transaction details:

• Shares were originally acquired through private placement on June 4, 2021
• Current total shares outstanding: 28,985,019
• Recent related sales in past 3 months:
  • Atlas Ventures Fund XII LP: 5,883 shares ($64,061.73) on May 6, 2025
  • Atlas Venture Associates XII LP: 48 shares ($498.84) on May 6, 2025
  • Atlas Ventures Fund XII LP: 16,132 shares ($159,222.84) on June 24, 2025

The filing indicates no knowledge of material adverse information regarding Jade Biosciences' operations that hasn't been publicly disclosed.

Positive

• None.

Negative

• Atlas Ventures Fund XII LP, a significant investor, has sold a total of 22,015 shares over two transactions in the past 2 months, with total proceeds of $223,284.57, indicating continued institutional selling pressure

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares of JBIO stock are being proposed for sale in the Form 144 filing from June 2025?

According to the Form 144 filing, 131 shares of Jade Biosciences, Inc. (JBIO) stock are proposed to be sold through Merrill Lynch, with an aggregate market value of $1,292.97.

What is the total number of JBIO shares outstanding as of June 2025?

As disclosed in the Form 144 filing, Jade Biosciences, Inc. (JBIO) has 28,985,019 shares outstanding as of June 2025.

When and how did the seller originally acquire the JBIO shares being sold?

The shares were originally acquired on June 4, 2021, through a Private Placement from the Issuer. The acquisition was paid for in cash on the same date.

What recent sales of JBIO stock were made by Atlas Ventures in the past 3 months?

Atlas Ventures made three recent sales: 1) Atlas Ventures Fund XII LP sold 5,883 shares on May 6, 2025, for $64,061.73 2) Atlas Venture Associates XII, LP sold 48 shares on May 6, 2025, for $498.84 3) Atlas Ventures Fund XII LP sold 16,132 shares on June 24, 2025, for $159,222.84.

What is the planned date of sale for the JBIO shares in this Form 144?

The Form 144 filing indicates an approximate date of sale of June 24, 2025, for the JBIO shares to be sold on the Nasdaq exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2025 - 04:59 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001845875
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Jade Biosciences, Inc.
SEC File Number	001-40544
Address of Issuer	221 CRESCENT ST. BUILDING 23, SUITE 105 WALTHAM MASSACHUSETTS 02453
Phone	(781) 312-3013
Name of Person for Whose Account the Securities are To Be Sold	Atlas Venture Associates XII, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Jade Biosciences, Inc.	Merrill Lynch One Bryant Park New York NY 10036	131	1292.97	28985019	06/24/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/04/2021	Private Placement	Issuer			131	06/04/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Atlas Ventures Fund XII LP 300 Technology Sq Ste 8 Cambridge MA 02139	Common	05/06/2025	5883	64061.73
Atlas Venture Associates XII, LP 300 Technology Sq Ste 8, Cambridge MA 02139	Common	05/06/2025	48	498.84
Atlas Ventures Fund XII LP 300 Technology Sq Ste 8 Cambridge MA 02139	Common	06/24/2025	16132	159222.84

144: Remarks and Signature

Remarks
Date of Notice	06/24/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Ommer Chohan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)